Romain Magnez

Mr. Romain Magnez

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
RMRomain Magnez
Romain Magnez
CBChristian Bailly
Christian Bailly
Xavier ThuruXavier Thuru
Xavier Thuru
The review highlights how protein–protein interactions (PPIs) have determining roles in most life processes and how interactions between protein partners are involved in various human diseases. The study of PPIs and binding interactions as well as their understanding, quantification and pharmacological regulation are crucial for therapeutic purposes. Diverse computational and analytical methods, combined with high-throughput screening (HTS), have been extensively used to characterize multiple types of PPIs, but these procedures are generally laborious, long and expensive. Rapid, robust and efficient alternative methods are proposed, including the use of Microscale Thermophoresis (MST), which has emerged as the technology of choice in drug discovery programs in recent years. This review summarizes selected case studies pertaining to the use of MST to detect therapeutically pertinent proteins and highlights the biological importance of binding interactions, implicated in various human diseases. The benefits and limitations of MST to study PPIs and to identify regulators are discussed.

8 May 2018 in Cancers
Verified
Journal Article
Open access
PDF file
FGFloriane Gibault
Floriane Gibault
MCMathilde coevoet
Mathilde coevoet
MSManon Sturbaut
Manon Sturbaut
AFAmaury Farce
Amaury Farce
NRNicolas Renault
Nicolas Renault
PCPhilippe Cotelle
Philippe Cotelle
Intrinsically disordered protein YAP (yes-associated protein) interacts with TEADs transcriptional factors family (transcriptional enhancer associated domain) creating three interfaces. Interface 3, between the Ω-loop of YAP and a shallow pocket of TEAD was identified as the most important TEAD zone for YAP-TEAD interaction. Using the first X-ray structure of the hYAP50–71-hTEAD1209–426 complex (PDB 3KYS) published in 2010, a protein-protein interaction inhibitors-enriched library (175,000 chemical compounds) was screened against this hydrophobic pocket of TEAD. Four different chemical families have been identified and evaluated using biophysical techniques (thermal shift assay, microscale thermophoresis) and in cellulo assays (luciferase activity in transfected HEK293 cells, RTqPCR in MDA-MB231 cells). A first promising hit with micromolar inhibition in the luciferase gene reporter assay was discovered. This hit also decreased mRNA levels of TEAD target genes.

4 April 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RBRaphaël Le Biannic
Raphaël Le Biannic
RMRomain Magnez
Romain Magnez
FKFrédérique Klupsch
Frédérique Klupsch
NLNatascha LELEU-CHAVAIN
Natascha LELEU-CHAVAIN
BTBryan Thiroux
Bryan Thiroux
RMRégis Millet
Régis Millet

11 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Xavier ThuruXavier Thuru
Xavier Thuru
RMRomain Magnez
Romain Magnez
HEHassiba El-Bouazzati
Hassiba El-Bouazzati
GVGerard VERGOTEN
Gerard VERGOTEN
Bruno QuesnelBruno Quesnel
Bruno Quesnel
CBChristian Bailly
Christian Bailly
Monoclonal antibodies targeting the PD-1/PD-L1 immune checkpoint have considerably improved the treatment of some cancers, but novel drugs, new combinations, and treatment modalities are needed to reinvigorate immunosurveillance in immune-refractory tumors. An option to elicit antitumor immunity against cancer consists of using approved and marketed drugs known for their capacity to modulate the expression and functioning of the PD-1/PD-L1 checkpoint. Here, we have reviewed several types of drugs known to alter the checkpoint, either directly via the blockade of PD-L1 or indirectly via an action on upstream effectors (such as STAT3) to suppress PD-L1 transcription or to induce its proteasomal degradation. Specifically, the repositioning of the approved drugs liothyronine, azelnidipine (and related dihydropyridine calcium channel blockers), niclosamide, albendazole/flubendazole, and a few other modulators of the PD-1/PD-L1 checkpoint (repaglinide, pimozide, fenofibrate, lonazolac, propranolol) is presented. Their capacity to bind to PD-L1 or to repress its expression and function offer novel perspectives for combination with PD-1 targeted biotherapeutics. These known and affordable drugs could be useful to improve the therapy of cancer.

16 November 2021 in Cancers
Verified
Journal Article
Open access
PDF file
NSNicolas Stoup
Nicolas Stoup
LMLiberelle Maxime
Liberelle Maxime
CSCeline Schulz
Celine Schulz
SCSumeyye Cavdarli
Sumeyye Cavdarli
RVRomain Vasseur
Romain Vasseur
Isabelle Van SeuningenIsabelle Van Seuningen
Isabelle Van Seuningen
The HER2 receptor and its MUC4 mucin partner form an oncogenic complex via an extracellular region of MUC4 encompassing three EGF domains that promotes tumor progression of pancreatic cancer (PC) cells. However, the molecular mechanism of interaction remains poorly understood. Herein, we decipher at the molecular level the role and impact of the MUC4EGF domains in the mediation of the binding affinities with HER2 and the PC cell tumorigenicity. We used an integrative approach combining in vitro bioinformatic, biophysical, biochemical, and biological approaches, as well as an in vivo study on a xenograft model of PC. In this study, we specified the binding mode of MUC4EGF domains with HER2 and demonstrate their “growth factor-like” biological activities in PC cells leading to stimulation of several signaling proteins (mTOR pathway, Akt, and β-catenin) contributing to PC progression. Molecular dynamics simulations of the MUC4EGF/HER2 complexes led to 3D homology models and identification of binding hotspots mediating binding affinity with HER2 and PC cell proliferation. These results will pave the way to the design of potential MUC4/HER2 inhibitors targeting the EGF domains of MUC4. This strategy will represent a new efficient alternative to treat cancers associated with MUC4/HER2 overexpression and HER2-targeted therapy failure as a new adapted treatment to patients.

16 June 2022 in Movement Disorders
Verified
Journal Article
Open access
ICIlda Coku
Ilda Coku
EMEugénie MUTEZ
Eugénie MUTEZ
SESabiha Eddarkaoui
Sabiha Eddarkaoui
SCSébastien Carrier
Sébastien Carrier
AMAntoine Marchand
Antoine Marchand
VHVincent Huin
Vincent Huin
Background: Pathogenic variants in the LRRK2 gene are a common monogenic cause of Parkinson's disease. However, only seven variants have been confirmed to be pathogenic.Objectives: We identified two novel LRRK2 variants (H230R and A1440P) and performed functional testing.Methods: We transiently expressed wild‐type, the two new variants, or two known pathogenic mutants (G2019S and R1441G) in HEK‐293 T cells, with or without LRRK2 kinase inhibitor treatment. We characterized the phosphorylation and kinase activity of the mutants by western blotting. Thermal shift assays were performed to determine the folding and stability of the LRRK2 proteins.Results: The two variants were found in two large families and segregate with the disease. They display altered LRRK2 phosphorylation and kinase activity.Conclusions: We identified two novel LRRK2 variants which segregate with the disease. The results of functional testing lead us to propose these two variants as novel causative mutations for familial Parkinson's disease. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society